MedInvent

MedInvent

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

MedInvent is a commercial-stage medical device company addressing a critical need in obstetrics: the precise execution of episiotomies to prevent severe perineal tears (OASIS). Its single, patented product, the EPISCISSORS-60™, is a physical guide that ensures clinicians can consistently achieve the angle recommended by global bodies like RCOG and FIGO. The device has achieved significant adoption in the UK's NHS and internationally, with multiple published studies and systematic reviews demonstrating a 50-60% relative reduction in OASIS rates, leading to substantial clinical benefits and cost savings for healthcare systems.

ObstetricsGynecology

Technology Platform

Patented surgical scissors with an integrated fixed-angle (60-degree) physical guide to standardize and accurately perform mediolateral episiotomies, eliminating operator variability.

Opportunities

Significant opportunity for further international expansion into markets that follow RCOG/FIGO guidelines, driven by compelling clinical and health economic data.
Potential to expand the product portfolio within the obstetric medical device space by addressing other common procedural variations or complications.

Risk Factors

Heavy reliance on a single product and vulnerability to any change in clinical guidelines regarding episiotomy technique.
Market contraction risk if overall episiotomy rates continue to decline based on 'no routine episiotomy' policies.
Potential for competitive entries seeking to replicate or improve upon the guided-angle concept.

Competitive Landscape

Competes primarily against standard, non-guided episiotomy scissors which are ubiquitous and low-cost. The value proposition is not against a direct device competitor, but against variable human technique. Barriers to entry include the company's strong IP, extensive clinical evidence base, and entrenched adoption in a major reference market (NHS).